Epidermolysis bullosa acquisita: current diagnosis and therapy

Christine R. Mehren,1 Robert Gniadecki2
1Department of Dermatology, Bispebjerg Hospital, Copenhagen; 2University of Copenhagen, Bispebjerg Hospital, Denmark

Abstract

Epidermolysis bullosa acquisita (EBA) is an acquired, autoimmune subepidermal blistering disease with an approximate prevalence of 0.2/million people. The hallmark of EBA is the presence of autoantibodies (mainly IgG class) to type VII collagen located at the dermal-epidermal junction. Clinically EBA is subdivided into the inflammatory and the non-inflammatory phenotypes, depending on the level of the cleavage in the basal membrane. A recent addition to the diagnostic techniques is the analysis of the serration pattern of the autoantibody deposits at the basal membrane in direct immunofluorescence. EBA and the closely related bullous systemic lupus erythematosus are the only diseases presenting with the so-called u-serration pattern which distinguishes them from many other autoimmune subepidermal blistering diseases. We also discuss the recent advances in therapy, including the experience with Rituximab.

Clinical features

Epidermolysis bullosa acquisita (EBA) was described for a century ago by Elliot.1 It is a rare disease with an approximate prevalence of 0.2/million people.2 EBA is an acquired, autoimmune cutaneous subepidermal blistering disease that primarily involves the skin, and sometimes mucous membranes. There is no racial or gender predilection. EBA often presents in the fourth to fifth decades of life. The hallmark of EBA is the presence of autoantibodies (mainly IgG class) to anchoring fibril collagen (type VII collagen) located at the dermal-epidermal junction. Clinically EBA is subdivided into the inflammatory and the non-inflammatory phenotypes, depending on the level of the cleavage in the basal membrane. A recent addition to the diagnostic techniques is the analysis of the serration pattern of the autoantibody deposits at the basal membrane in direct immunofluorescence. EBA and the closely related bullous systemic lupus erythematosus are the only diseases presenting with the so-called u-serration pattern which distinguishes them from many other autoimmune subepidermal blistering diseases. We also discuss the recent advances in therapy, including the experience with Rituximab.

Diagnostic techniques

The first diagnostic criteria for EBA were established in the early 1970s by Roenigk and associates. They were i) spontaneous or trauma-induced blisters resembling hereditary dystrophic EB, ii) adult onset, iii) a negative family history for EB, and iv) the exclusion of all other bullous diseases.17 However, since then at least 53 verified cases of childhood EBA have been reported in the literature, mainly of the inflammatory subtype.18 In addition a diagnosis of EBA cannot be done reliably solely by clinical findings, because of the variable clinical and histological presentations.

Immunofluorescence techniques remain the cornerstone of the diagnosis of EBA and have increasingly replaced the immunoelectron microscopy (IEM) as the gold standard.19 Other investigative diagnostic techniques are immunoblotting, ELISA, and immunoprecipitation. Direct Immunofluorescence (DIF) on perilesional skin demonstrates linear immune deposits of immunoreactants, mainly IgG, at the basement membrane zone. However deposits of IgA, IgM, C3, C4, or properdin may be detected as well. In EBA deposits of IgG in the absence of C3 is seen more commonly than in BP. Furthermore, deposits of multiple conjugates (including IgG, IgA, IgM, C3, C4, or properdin) are seen more frequently in the setting of EBA.20 Indirect immunofluorescence (IIF) can detect the presence of circulating IgG autoantibodies, directed against type VII collagen in the basement membrane, it usually detects the IgG autoantibodies that binds to the dermal floor on salt split skin. Salt split skin substrate can be used to distinguish EBA and bullous pemphigoid (BP), because IgG autoantibodies from patients with bullous pemphigoid bind to the epidermal roof (upper part) of salt-split skin. If the antibody labels the dermal side of the separation, the patient usually has either EBA or bullous SLE (there are, however, other diseases with dermal staining: anti-elpligrin (lamina-5), Cicatricial pemphigoid, Chan’s disease, Zilliken’s disease and Ghohestani’s disease).21

A breakthrough in the diagnostics was the observation of specific serration patterns in the autoantibody deposits at the basement membrane in direct immunofluorescence. Besides a true linear staining pattern, two DIF immunodeposition patterns have been described i) a u-serrated staining pattern is typical of EBA, and ii) an n-serrated staining pattern in other subepidermal immunobullous diseases.22 The binding of autoantibodies in EBA to type VII collagen, can ultrastructurally be seen as upstanding arms between the rootlets of the basal keratinocytes, resulting in u shapes. Consequently these two distinct patterns can be applied in order to differentiate EBA from other pemphigoid variants by DIF only. The type of serration in the case of IgA and IgG is similar, however, in the case of IgA it is more easily recognized due to better fluorescence image contrast. Diseases such as IgA-mediated EBA and inflammatory EBA may look like BP, however, using the serration patterns algorithm, patients with EBA who otherwise would have been erroneously diagnosed can be detected.

Immunoelectron microscopy (IEM) documents the localization of the immune deposits within the dermal-epidermal junction of the skin of EBA patients. By direct immunoelec-
Table 1. Comparison of the clinical and immunopathological features of subepidermal blistering diseases.

| Subepidermal immunobullous disease | Clinical Characteristic features | DIF | Binding on salt split skin | Serration pattern |
|-----------------------------------|----------------------------------|-----|-----------------------------|------------------|
| Bullous pemphigoid (BP)           | Elderly, most common autoimmune blistering disease. Tense blisters on inflamed or non inflamed skin. Pruritus common, variable severity. More common in patients with multiple sclerosis. Predilection sites: the inner or anterior thighs, groins, flexor surfaces of the upper extremities and lower abdomen. Oral mucosal lesions are rare. | IgG and C3 or C3 alone (+ weaker staining IgM, IgA) at the dermal-epidermal junction. | Epidermal (few dermal) | n-serrated<sup>6</sup> |
| Pemphigoid gestationis           | During pregnancy and/or puerperium; urticarial plaques and/or tense blisters. Pruritus typically severe. Predilection sites: umbilical and periumbilical regions; trunk and extremities. | Linear deposition of C3 ± IgG at the dermal-epidermal junction. | Epidermal | As BP; n-serrated |
| Lichen planus pemphigoides       | Usually benign, tense blisters and lesions of lichen planus (usually persistent) on top of lichen planus lesions or on clinically normal skin. Predilection sites: the extremities, trunk and oral mucosa. | Linear deposits of IgG at the dermal-epidermal junction. | Epidermal | Unknown |
| Mucous membrane pemphigoid       | Elderly (female) patients. Tense blisters and erosions with scar formation. Predilection sites: mucosa of the mouth, eyes, nose, larynx; eosohagus or anogenital regions. | In anti-BP180 MMP and antilamin 332 MMP: linear IgG, ±C3 occasionally IgA. | Epidermal in anti-BP 180 MMP and ocular MMP | n-serrated<sup>6</sup> |
| Dermatitis herpetiformis         | Adult patients. Erythematous papules, urticarial plaques, papulovesicles, vesicles and rarely bullae, isolated or in herpetiform grouping often healing with scar formation. Intensely pruritic. Predilection sites: symmetrically distributed lesions on extensor surface of the extremities, scalp, nape, shoulders, sacral region and buttocks. | Granular papillary and basement membrane IgA. | Negative | Irrelevant |
| Linear IgA disease               | Papulovesicular eruption in cluster of jewels configuration. Pruritic (ranging from mild to severe). Predilection sites: trunk, extemmites, the face, abdomen and perineum. Frecquent mucous membrane involvement (may induce severe complications). | Linear IgA (rarerly granular) at the dermal-epidermal junction. | Epidermal (few dermal) | n-serrated<sup>6</sup> |
| Linear IgAVIgG bullous dermatosis<sup>12</sup> | Resemble the lesions of BP, annular vesicobulous lesions with frequent involvement of the oral mucosa. Predilection sites: no specific | Linear IgA and IgG ± C3 at the dermal-epidermal junction. | Epidermal (few dermal or both epidermal and dermal) | Probably n-serrated<sup>6</sup> |
| Anti-p450-pemphigoid<sup>13</sup> | Only one case in literature, Fujiwara et al.<sup>18</sup> | Only one case in literature, Fujiwara et al.<sup>18</sup> | Epidermal<sup>13</sup> | Unknown |
| Anti-p200 pemphigoid<sup>12</sup> | Often resembles BP; could resemble dermatitis herpetiformis, linear IgA disease or EBA. Could involve mucous membranes. Often coexisting psoriasis. (rapid response to treatment) | Linear IgG and C3 at the dermal-epidermal junction. | Dermal | n-serrated<sup>6</sup> |
| Epidermolysis bullosa acquisita   | Classical EBA: skin fragility, trauma- induced blisters and erosions. Predilection sites: extensor surfaces of the extremities. | Linear IgG (± IgA, IgM), C3 at the dermal-epidermal junction. | Dermal | u-serrated<sup>6</sup> |
|                                   | Inflammatory EBA: widespread eruptions of tense blisters on erythematous or normal appearing skin. Predilection sites: usually on flexural and/or intertriginous areas. + mucous membrane lesions | | | |
| Bullous SLE                       | Mainly adult patients. Tense blisters on normal or erythematous skin, eruptions usually in a herpetiform arrangement in patients with SLE. Pruritus may be severe. Predilection sites: trunk and flexural surfaces. Frequently oral lesions. | Linear or granular depositions of IgG (± IgM, IgA, C3) at the dermal-epidermal junction. | Dermal (rarely epidermal or combined binding) | u-serrated<sup>6</sup> |
| Anti-p105-pemphigoid<sup>16</sup> | Bullae and erosions on mucous membrane and skin, resembling toxic epidermal necrolysis or pemphigus vulgaris<sup>11</sup> | Linear IgG and C3 deposition at the skin basement membrane zone<sup>13</sup> | Dermal<sup>13</sup> | Unknown |
tron microscopy the ultrastructural localization of in vivo-bound IgG autoantibodies at the basement membrane is documented. With indirect immunoelectron microscopy the binding site of circulating IgG autoantibodies at the basement membrane is detected. IEM detects IgG autoantibodies at the lamina densa and sublamina densa areas of skin basement membrane. Bullous pemphigoid IgG autoantibodies, on the contrary, are localized to the hemidesmosome and upper lamina lucida.26

Immunoblotting represents a sensitive detection method for EBA.21 EBA sera will bind to a 290-KDa band in Western blots of human skin basement membrane proteins containing type VII collagen, whereas sera from all other primary blistering diseases will not. This band corresponds to a single alpha chain of the type VII collagen, whereas sera from all other primary blistering diseases will not. This band corresponds to a single alpha chain of the type VII collagen homotrimer molecule.22 Western blotting differentiates between anti-p200 pemphigoid and EBA. To distinguish between the latter two disorders, patients’ sera have to be subjected to Western blotting of extract from human dermis and then react with 200 and 290 kDa proteins in antip-200 pemphigoid and EBA, respectively.2

ELISA (Enzyme-linked immunosorbent assay) documents the specific basement membrane antigen recognized by the patient’s IgG circulating autoantibodies. The ELISA method identifies non-denatured, nonreduced proteins and is more sensitive than immunoblotting, which only detects denatured, reduced proteins.7

Treatment

Compared with other autoimmune blistering diseases, EBA has a decreased responsiveness to therapy. Inflammatory EBA, EBA presenting in children and IgA-EBA, respond more favourably to the conventional treatment approach of high-dose corticosteroids and corticosteroid sparing agents. In most cases of IgA-EBA, the skin lesions respond to therapy with dapsone alone.

Dapsone and low-dose prednisone are usually effective in treating childhood EBA.34 However, high doses of corticosteroids are not recommended as maintenance therapies as the adverse effects of corticosteroids are both time and dose dependent.

Non-inflammatory (classical) EBA is often refractory to systemic corticosteroids, azathioprine, methotrexate, and cyclophosphamide.21 Therapeutic options that have proven effective in retrospective observations include extracorporeal photochemotherapy (ECP), i.e. immunoglobulin (IVIG), and Rituximab.

The treatment of EBA patients with IVIG has shown encouraging results. In one retrospective analysis two patients with severe EBA were treated with monthly cycles of IVIG. One of the patients had a complete response, defined as absence of lesions for more than 4 weeks without any treatment. The other patient responded to the treatment, however, due to metastatic lung cancer the treatment was discontinued.24 Another case describes a patient treated with 6 cycles of IVIG at a dose of 400 mg/kg per day for 5 consecutive days (repeating the cycle every 4 weeks). After the second cycle, most of the erosions had healed and marked remission was observed during the 6-month follow-up period. The patient did not experience any negative side effects.25

Patients that have had unsatisfactory response to steroid, immunosuppressive agents and IVIG may benefit from the therapy with rituximab. This monoclonal antibody reacting against CD20 depletes mature, autoreactive B-cells. Of the reported cases of EBA patients treated with rituximab, either complete remission or very good partial remissions have been reported. In one retrospective analysis the patient, a 58-year old woman, had to be hospitalized due to the severity of EBA. She had extensive cutaneous and oral ulceration, cellulitis and a deep vein thrombosis secondary to immobility.

After four rituximab infusions at a dose of 375 mg m², she experienced complete remission.26 Another patient, a 54-year-old woman experienced a partial remission within a month after the onset of rituximab. After twelve rituximab infusions at a dose of 375 mg m², she experienced almost complete cutaneous clearance with improved oral intake and mobility.27 Rituximab can safely be combined with high-dose IVIG, which may exert a synergistic effect and simultaneously protect against serious infection-related adverse events.28,29

Long-term ECP has been reported to induce remission in three patients with drug resistant, aggressive cases of EBA.30 ECP is based on separation of a leukocyte/lymphocyte-enriched cell fraction from the peripheral blood, extracorporeal treatment of the cells with 8-MOP-UVA, and subsequent reinfusion of the cells in the patient. The main effects in EBA seem to consist in inhibition of pathogenetic autoantibody production by B lymphocytes and generation of regulatory T cells.

When treating a patient with EBA, it is important to be aware of coexisting systemic diseases that might influence the choice of therapy.

Among the systemic diseases reported in association with EBA, are malignancies and autoimmune diseases.32 Inflammatory bowel disease (IBD) is one of the more common systemic illnesses associated with EBA; 25% of EBA patients have IBD.33 There are a few cases of EBA patients with coexisting psoriasis.33 Ultraviolet radiation is not a treatment option in this case as it has been demonstrated that it can induce blistering in patients with EBA.33

References

1. Elliott GT. Two cases of epidermolysis bullosa. J Cutan Genitourin Dis 1895;13:108.
2. Ishii N, Hamada T, Dainichi T, et al. Epidermolysis bullosa acquisita; what’s new. J Dermatol 2010;37:220-30.
3. Zhu XJ, Niimi Y, Bystryn JC. Epidermolysis bullosa acquisita. Incidence in patients with basement membrane zone antibodies. Arch Dermatol 1990;126:171-4.
4. Sitaru C, Kromminga A, Hashimoto T, et al. Autoantibodies to type VII collagen mediate Fcgamma-dependent granulocyte activation and induce dermal-epidermal separation in cryosections of human skin. Am J Pathol 2002;161:301-11.
5. Tanka H, Ishida, Yamamoto A, et al. A novel variant of acquired epidermolysis bullosa with autoantibodies against the central triple-helical domain of type VII collagen. Lab Invest 1997;77:623-32.
6. Ronengik HH, Ryan JG, Bergfeld WF. Epidermolysis bullosa acquisita. Report of three cases and review of all published cases. Arch Dermatol 1971;103:1-10.
7. Lehman JS, Camilleri MJ, Gibson SE. Epidermolysis bullosa acquisita: concise review and practical considerations. Int J Dermatol 2009;48:227-36.
8. Mihai S, Sitaru C. Immunopathology and molecular diagnosis of autoimmune bullous diseases. J Cell Mol Med 2007;11:462-81.
9. Vodegel RM, Jonkman MF, Pas HH, De Jong MC. U-serrated immunodeposition pattern differentiates type VII collagensen-targeting bullous disease from other subepidermal bullous autoimmune diseases. Br J Dermatol 2004;151:112-8.
10. Natsuga K, Nishie W, Shinikuma S, et al. Circulating IgA and IgE autoantibodies in antilaminin-332 mucous membrane pemphigoid. Br J Dermatol 2010;162:513-7.
11. Smith EP, Taylor TB, Meyer LJ, Zone JJ. Identification of a basement membrane zone antigen reactive with circulating IgA antibody in ocular cicatricial pemphigoid. J Invest Dermatol 1993;101:619-23.
12. Shimizu S, Natsuga K, Shinikuma S, et al. Localized linear IgA/IgG dermatosis. Acta Derm Venereol 2009;90:621-4.
13. Georgi M, Jainta S, Bröcker EB, Zillikens D. Autoantigens of subepidermal bullous autoimmune dermatoses. Hautarzt 2001; 52:1079-89.
14. Fujiwara S, Shinkai H, Takayasu S, et al. A case of subepidermal blister disease associated with autoantibody against 450 kD protein. J Dermatol 1992;19:610-3.
15. Chen KR, Shimizu S, Miyakawa S, et al. Coexistence of psoriasis and an unusual IgG-mediated subepidermal bullous der-
matosis: identification of a novel 200-kDa lower lamina lucida target antigen. Br J Dermatol 1996;134:340-6.

16. Chan LS, Cooper KD. A novel immune-mediated subepidermal bullous dermatosis characterized by IgG autoantibodies to a lower lamina lucida component. Arch Dermatol 1994;130:343-7.

17. Roenigk HH Jr, Ryan JG, Bergfeld WF. Epidermolysis bullosa acquisita. Report of three cases and review of all published cases. Arch Dermatol 1971;103:1-10.

18. Mayuzumi M, Akiyama M, Nishie W, et al. Childhood epidermolysis bullosa acquisita with autoantibodies against the noncollagenous 1 and 2 domains of type VII collagen: case report and review of the literature. Br J Dermatol 2006;155:1048-52.

19. Woodley D, Remington J, Chen M. Autoimmunity to type VII Collagen: Epidermolysis Bullosa Acquisita. Clin Rev Allerg Immunol 2007;33:78-84.

20. Vodegel RM, de Jong MC, Pas HH, Jonkman MF. IgA-mediated epidermolysis bullosa acquisita: Two cases and review of the literature. J Am Acad Dermatol 2002;6:919-25.

21. Schmidt E, Zillikens D. Research in practice: diagnosis of subepidermal autoimmune bullous disorders. J Dtsch Dermatol Ges 2009;7:296-300.

22. Woodley DT, Briggaman RA, O’Keefe EJ, et al. Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita. N Engl J Med 1984;310:1007-13.

23. Hallel-Haley, Nadelman C, Chen M, Woodley DT. Epidermolysis bullosa acquisita: update and review. Clin Dermatol 2001;19:712-8.

24. Sanli H, Akay BN, Ayyildiz E, et al. Remission of severe autoimmune bullous disorders induced by long-term extracorporeal photochemotherapy. Transf Apheres Sci 2010;43:353-9.

25. Segura S, Iranzo P, Martínez-de Pablo I, et al. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases. J Am Acad Dermatol 2007;56:960-7.

26. Gourgiotou K, Exadaktylou D, Aroni K, et al. Epidermolysis bullosa acquisita: treatment with intravenous immunoglobulins. J Eur Acad Dermatol Venereol 2002;16:77-80.

27. Crichlow SM, Mortimer NJ, Harman KE. A successful therapeutic trial of rituximab in the treatment of a patient with calcificant high-titre epidermolysis bullosa acquisita. Br J Dermatol 2007;156:194-6.

28. Saha M, Cutler T, Bhogal B, et al. Refractory epidermolysis bullosa acquisita: successful treatment with rituximab. Clin Exp Dermatol 2009;34:e979-e980.

29. Peterson JD, Chan LS. Effectiveness and side effects of anti-CD20 therapy for autoantibody-mediated blistering skin diseases: A comprehensive survey of 71 consecutive patients from the Initial use to 2007. Ther Clin Risk Manag 2009;5:1-7.

30. Schmidt E, Bröcker E-B, Goebeler M. Rituximab in treatment-resistant autoimmune bullous skin disorders. Clin Rev Allerg Immunol 2008;34:56-64.

31. Chen M, O’Toole EA, Sanghavi J, et al. The epidermolysis bullosa acquisita antigen (Type VII Collagen) is present in human colon and patients with Cron’s disease have Autoantibodies to Type VII Collagen. J Invest Dermatol 2002;6:1059-64.

32. Kabashima R, Hino R, Bito T, et al. Epidermolysis bullosa acquisita associated with psoriasis. Acta Dermatol Venereol 2010;90:314-6.

33. Jappe U, Zillikens D, Bonnekoh B, Gollnick H. Epidermolysis bullosa acquisita with ultraviolet radiation sensitivity. Br J Dermatol 2000;142:517-20.
